Bayesian Dosing Simulator ( BDS ): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-05 · 46 (5)
DOI: 10.1002/phar.70148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 29.04.2026. Verfasst von Adrian Valadez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Models, Biological, Meropenem. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Midwestern University, NIH HHS.
Abstract (Originalsprache)
Background
Meropenem is widely used to treat hospital‐acquired pneumonia in critically ill patients, with efficacy dependent on the time that free concentrations exceed the minimum inhibitory concentration ( f T > MIC). In practice, single‐sample therapeutic drug monitoring (TDM) may not ensure target attainment, particularly in patients requiring continuous renal replacement (CRRT). Model‐informed precision dosing (MIPD) enables individualized, real‐time adjustments, but implementation is limited. Herein, we developed a Shiny application for Bayesian meropenem dose optimization.
Methods
A previously published nonparametric model was translated into a parametric Bayesian framework with maximum a posteriori (MAP) updating implemented through a Shiny interface. Plasma pharmacokinetic (PK) data from critically ill patients served for external validation. Posterior predictions were benchmarked against population and individual (MAP) outputs from Pmetrics 3.09 and population median profiles from 1000 Monte Carlo simulations per patient. Predictive performance was assessed using relative median prediction error ( r MPE) and relative median absolute prediction error ( r MAPE), for the combined cohort overall and stratified by CRRT status. Sparse sampling scenarios (one, two, and three observations per patient) were also evaluated.
Results
Eighteen patients were evaluated (non‐CRRT n = 13; CRRT n = 5). In Pmetrics, r MPE ranged from −7.7% to 9.4% and r MAPE from 18.5% to 25.5% across renal replacement strata and prediction types. Simulation‐based population predictions yielded greater error, with r MPE/ r MAPE of −25%/34% in CRRT patients and −21%/30% in non‐CRRT patients. Across Bayesian Dosing Simulator (BDS) sampling scenarios, prediction error remained within prespecified limits ( r MPE ±20%, r MAPE ≤ 30%), with F20 ranging from 80% to 94% and F30 from 87% to 94%.
Conclusion
A validated nonparametric meropenem model was successfully implemented within an open‐source Bayesian framework yielding predictive accuracy comparable to the reference model with robust performance under sparse sampling, supporting its feasibility for individualized meropenem dosing. Prospective evaluation of its clinical safety and effectiveness is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, Illinois, USA.
- Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, Illinois, USA.
- Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois, USA.
- Departments of Pharmacology and Biomedical Sciences, College of Graduate Studies, Midwestern University, Downers Grove, Illinois, USA.
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
- Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute, Children's Hospital of Los Angeles, Los Angeles, California, USA.
ORCID-Profile: Adrian Valadez, Marc H Scheetz, Michael N Neely, Helen K Donnelly, Erin Korth, Richard G Wunderink, Nathaniel J Rhodes
Förderung
- NIAID NIH HHS
- Midwestern University
- NIH HHS
- National Institutes of Health
Zitieren
APA
Valadez, A., Scheetz, M. H., Neely, M. N., Donnelly, H. K., Korth, E., Wunderink, R. G., & Rhodes, N. J. (2026). Bayesian Dosing Simulator ( BDS ): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(5). https://doi.org/10.1002/phar.70148
Vancouver
Valadez A, Scheetz MH, Neely MN, Donnelly HK, Korth E, Wunderink RG, et al. Bayesian Dosing Simulator ( BDS ): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(5). doi:10.1002/phar.70148
BibTeX
@article{Valadez2026,
author = {Valadez, Adrian and Scheetz, Marc H and Neely, Michael N and Donnelly, Helen K and Korth, Erin and Wunderink, Richard G and Rhodes, Nathaniel J},
title = {Bayesian Dosing Simulator ( BDS ): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
volume = {46},
number = {5},
doi = {10.1002/phar.70148}
}
EUVIMED